0 Kommentare

CAPR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 29, 2026 - Seite 2

On July 29, 2026, the AdCom met to discuss the Deramiocel BLA, and the panel, in a non-binding 9-3 vote, "concluded that the available evidence does not support the efficacy of deramiocel for treating DMD-associated cardiomyopathy." On this news, Capricor's stock fell $2.38, or 36%, to close at $4.19 per share on July 30, 2026, on unusually heavy trading volume.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Capricor's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Capricor class action, go to www.faruqilaw.com/CAPR or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Frequently Asked Questions (FAQ) for Investors Regarding the Capricor Securities Class Action Lawsuit:

What is the Capricor securities fraud lawsuit about?

The lawsuit alleges that Capricor Therapeutics, Inc. (NASDAQ: CAPR) and certain of its officers and directors made materially misleading statements and omissions regarding the regulatory prospects for Deramiocel, the Company's therapy for Duchenne muscular dystrophy. Specifically, the complaint alleges that the Company adopted changes to the pre-specified statistical analysis plan used to analyze Deramiocel's clinical data without first obtaining FDA agreement to those changes before resubmitting the Deramiocel Biologics License Application. As a result of these allegedly undisclosed circumstances, the lawsuit contends that there was a significant risk the FDA could conclude that the clinical results did not provide substantial evidence of Deramiocel's effectiveness, creating a substantial risk to the drug's regulatory approval. Investors allegedly suffered losses when, on July 27, 2026, the FDA released briefing documents stating that the benefit-risk assessment for Deramiocel appeared unfavorable in the absence of evidence of effectiveness, causing Capricor's stock to fall approximately 64%, and again on July 30, 2026, following the AdCom panel's non-binding 9-3 vote concluding that available evidence does not support Deramiocel's efficacy for DMD-associated cardiomyopathy, causing the stock to fall an additional approximately 36%.

◄ Seite 1 Seite 2 von 4 Seite 3 ►